[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$bmys
$BMYs faces a setback as the FDA rejects a key application, leading to downgrades. However, positive analysis suggests potential for future growth and market expansion.
About $bmys
A pharmaceutical company.
Insights #
- $bmys creators is up XX% from the previous week.
- $bmys mentions is up XX% from the previous week.
Engagements: XXX #
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XXX
1 Month: XXXXX +314%
1-Year High: XXX on 2025-05-15
1-Year Low: X on 2025-06-22
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X +50%
1 Month: X +50%
1-Year High: X on 2025-04-27
1-Year Low: X on 2025-04-29
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $bmys in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1 Week: X +50%
1 Month: X +50%
1-Year High: X on 2025-04-27
1-Year Low: X on 2025-04-29
Top topics mentioned In the posts about $bmys in the last XX hours
hc, $barcl, rating agency, combo, investment, $2b, superior, dec
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$REPL Replimune rebounds despite FDA rejection and multiple downgrades via Shares plummeted -XX% on Tuesday after FDA rejected RP1 application for advanced melanoma (combo with $BMYs Opdivo) Wednesday rebound: +24.24% despite analyst downgrades BMO: Downgrade to Underperform PT cut to $X Barclays: Downgrade to Equal Weight PT slashed to $X (from $17) H.C. Wainwright: Downgrade to Neutral from Buy Concerns over funding and need to rerun clinical trials per FDA feedback"
@overnight_stock on X 2025-07-23 15:37:27 UTC XXX followers, XXX engagements
"Long Cytokinetics $CYTK. My analysis points to a $XX PT (+36% upside)-1 year timeframe. Thesis: Aficamten PDUFA: Dec XX 2025. High probability of approval for oHCM. Superior Profile: Better efficacy & safety vs. $BMY's Camzyos. TAM Expansion: ACACIA trial in nHCM could unlock a $2B+ market. Funded: Cash runway through commercialization. #Biotech #Investing #Cardiology #PDUFA"
@bs2537 on X 2025-07-21 18:30:35 UTC 7863 followers, 1178 engagements